异丙托溴铵反应性对慢性鼻炎后鼻神经干预结局的预测价值
本研究回顾性分析81例慢性鼻炎患者,评估异丙托溴铵反应性对后鼻神经手术神经切断术或诊室消融结局的预测作用。结果显示,异丙托溴铵反应阳性者可能更受益于诊室消融,但对手术神经切断术的结局无预测价值。
要点
- 异丙托溴铵反应阳性可预测诊室后鼻神经消融的临床显著改善。
- 手术神经切断术后,反应阳性与阴性者临床显著改善率相似。
- 异丙托溴铵反应性不应作为手术神经切断术的患者筛选依据。
核心结论
- 异丙托溴铵反应阳性者可能更受益于后鼻神经诊室消融技术。
- 异丙托溴铵反应性对手术后鼻神经切断术结局无预测价值,反应阳性与阴性者均可获益。
研究设计与样本
- 回顾性综述,纳入2013年1月至2025年6月期间 trial 过异丙托溴铵鼻喷雾并接受后鼻神经手术神经切断术或诊室消融的慢性鼻炎患者。
- 共纳入81例患者(男43例,女38例;平均年龄57.9岁),其中44例(54.3%)自我报告对异丙托溴铵有反应。
- 结局采用SNOT-22问卷评估,重点关注鼻科组分。
主要发现
- 诊室后鼻神经消融后SNOT-22鼻科子域评分显著改善(17.7 ± 5.8降至14.5 ± 7.1,P = .04)。
- 手术神经切断术后SNOT-22鼻科子域评分显著改善(19.1 ± 6.7降至15.8 ± 7.3,P = .02)。
- 手术神经切断术后,异丙托溴铵反应阳性者鼻后滴漏显著改善(P = .03),反应阴性者鼻漏显著改善(P = .04),两组SNOT-22鼻科子域达到MCID的比例相似(45.2% vs 50.0%,P = .73)。
- 诊室消融后,异丙托溴铵反应阳性者达到MCID的比例显著更高(64.7% vs 27.8%,P = .03),鼻漏(P = .03)、浓稠鼻分泌物(P = .03)及鼻科子域评分(P = .03)均显著改善,反应阴性者无显著症状变化。
临床怎么用
- 对异丙托溴铵反应阳性的慢性鼻炎患者,可优先考虑后鼻神经诊室消融。
- 手术后鼻神经切断术的获益不依赖于异丙托溴铵反应性,反应阴性者也可考虑手术。
局限性
- 回顾性研究设计。
- 异丙托溴铵反应性为患者自我报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Procedures targeting the posterior nasal nerve (PNN) are effective in treating chronic rhinitis after failed medical therapy. We evaluate how ipratropium response predicts PNN intervention outcomes. STUDY DESIGN: Retrospective review from January 2013 to June 2025. STUDY SETTING: Tertiary academic center. METHODS: We reviewed patients with chronic rhinitis who trialed ipratropium nasal spray and received PNN surgical neurectomy or in-office ablation (cryotherapy or radiofrequency ablation). Ipratropium responsiveness was self-reported. Outcomes were assessed with the SNOT-22 questionnaire, focusing on rhinologic components. RESULTS: 81 patients (43 male, 38 female; mean age 57.9 years) were included, of whom 44 (54.3%) reported response to ipratropium. SNOT-22 rhinologic subdomain scores improved significantly following both in-office PNN ablation (17.7 ± 5.8-14.5 ± 7.1, P = .04) and surgical neurectomy (19.1 ± 6.7-15.8 ± 7.3, P = .02). After PNN surgical neurectomy, ipratropium responders demonstrated significant improvement in postnasal drip (P = .03), nonresponders in rhinorrhea (P = .04), and both had similar rates of clinically meaningful improvement (MCID) in the SNOT-22 rhinologic subdomain (45.2% vs 50.0%, P = .73). In contrast, for in-office PNN ablation, ipratropium responders had a significantly higher rate of MCID achievement (64.7% vs 27.8%, P = .03) and significant improvements in rhinorrhea (P = .03), thick nasal discharge (P = .03), and rhinologic subdomain scores (P = .03), while nonresponders had no significant symptom changes following in-office ablation. CONCLUSION: Patients with positive response to ipratropium may be more likely to benefit from PNN in-office ablation techniques. Ipratropium response is not predictive of outcome for surgical PNN neurectomy, as both responders and nonresponders may experience benefit.
引用
- Maddineni S, Hwang PH, Ayoub NF, et al. Predictive Value of Ipratropium Responsiveness on Posterior Nasal Nerve Neurectomy Outcomes in Chronic Rhinitis. Otolaryngol Head Neck Surg. 2025. PMID: 41474181. doi:10.1002/ohn.70099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。